Crescita TherapeuticsTSX:CTX 20 Days Inventory is 135.61 as of Mar. 2026, which is 35% below its 10-year median of 207.99. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Crescita Therapeutics ranks better than 52.44% on this metric.
The historical rank and industry rank for Crescita Therapeutics's Days Inventory or its related term are showing as below:
TSX:CTX'
s Days Inventory Range Over the Past 10 Years
Min: 158.14 Med: 207.99 Max: 302.61
Current: 158.14
During the past 12 years, Crescita Therapeutics's highest Days Inventory was 302.61. The lowest was 158.14. And the median was 207.99.
TSX:CTX's Days Inventory is ranked better than 52.44% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs TSX:CTX: 158.14
Crescita Therapeutics's Days Inventory
declined
from Mar. 2025 (212.19) to Mar. 2026 (135.61).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Crescita Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.67.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Crescita Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.79.
Crescita Therapeutics (TSX:CTX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Crescita Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Crescita Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Crescita Therapeutics Days Inventory Related Terms
Crescita Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a Days Inventory of 135.61 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Crescita Therapeutics and its competitors. This is 35% below median its historical median of 207.99. Over the past decade, Crescita Therapeutics' Days Inventory has ranged from 158.14 to 302.61. According to the industry distribution chart, Crescita Therapeutics ranks #439 out of 923 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Crescita Therapeutics' Days Inventory too high?
Crescita Therapeutics' current Days Inventory of 135.61 is 35% below median its 10-year median of 207.99. Over the past 10 years, this metric has ranged from a low of 158.14 to a high of 302.61. The Drug Manufacturers industry median Days Inventory is 164.48. Crescita Therapeutics' value of 135.61 is 17.6% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #439 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #439 out of 923 companies for Days Inventory. This puts Crescita Therapeutics in the upper half of its industry. The industry median Days Inventory is 164.48. Crescita Therapeutics' value of 135.61 is 17.6% below this benchmark. Historically, Crescita Therapeutics' own Days Inventory has ranged from 158.14 to 302.61 over the past decade. While the company's 10-year median is 207.99 vs. the industry median of 164.48, Crescita Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current Days Inventory of 135.61 is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current Days Inventory is 135.61, which is 35% below median its own 10-year median of 207.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Days Inventory is 135.61, which is 35% below median its 10-year median of 207.99 and 17.6% below the Drug Manufacturers industry median of 164.48. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Days Inventory is 135.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
Days Inventory: 135.61 (35% below median its 10-year median of 207.99)
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
Industry Position: 17.6% below the Drug Manufacturers median (#439 of 923)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
